Table 2.
Baseline characterization and comparison.
| Variables | Total (n = 808) | Pulmonary infection after chemotherapy for lung cancer | P | |
|---|---|---|---|---|
| No (n = 404) | Yes (n = 404) | |||
| Age | 65.00 [59.00, 70.00] | 65.00 [58.00, 71.00] | 65.00 [59.00, 69.00] | 0.985 |
| BMI | 21.50 [19.70, 23.70] | 21.80 [19.50, 24.10] | 21.20 [19.80, 23.40] | 0.129 |
| Chemotherapy cycles | 5.00 [2.00, 8.00] | 3.00 [1.00, 5.00] | 7.00 [5.00, 11.00] | <0.001 |
| Hospitalizations | 7.00 [4.00, 12.00] | 4.50 [2.00, 7.00] | 10.00 [6.00, 15.30] | <0.001 |
| WBC | 6.90 [5.49, 9.17] | 6.56 [5.19, 8.78] | 7.07 [5.93, 9.55] | <0.001 |
| RBC | 3.77 [3.30, 4.15] | 3.76 [3.28, 4.17] | 3.78 [3.33, 4.15] | 0.943 |
| HGB | 112.00 [99.90, 125.00] | 112.00 [99.00, 125.00] | 112.00 [101.00, 124.00] | 0.603 |
| PLT | 209.00 [160.00, 258.00] | 208.00 [161.00,268.00] | 212.00 [160.00,241.00] | 0.357 |
| NEUT | 72.10 [64.30, 79.20] | 70.60 [63.10, 78.30] | 74.10 [66.00, 79.60] | <0.001 |
| LYM | 17.30 [12.00, 23.30] | 18.80 [12.80, 25.10] | 16.10 [11.50, 21.60] | <0.001 |
| MONO | 7.30 [5.40, 9.48] | 7.40 [5.50, 9.73] | 7.11 [5.20, 9.10] | 0.147 |
| NLR | 4.38 [2.83, 7.09] | 3.74 [2.53, 6.10] | 4.90 [3.33, 7.67] | <0.001 |
| NMR | 10.10 [7.11, 14.40] | 9.34 [6.74, 13.20] | 10.90 [7.57, 15.40] | <0.001 |
| NPR | 0.35 [0.27, 0.43] | 0.33 [0.26, 0.42] | 0.36 [0.29, 0.44] | 0.001 |
| IBIL | 7.30 [5.70, 9.39] | 7.00 [5.31, 9.42] | 7.45 [6.10, 9.31] | 0.007 |
| ALT | 18.00 [12.70, 26.30] | 17.90 [13.00, 28.30] | 18.20 [12.30, 24.90] | 0.218 |
| AST | 23.40 [19.40, 29.40] | 23.80 [18.90, 29.80] | 23.20 [19.80, 28.70] | 0.858 |
| TBIL | 9.89 [7.63, 12.60] | 9.46 [7.22, 12.70] | 10.10 [8.08, 12.30] | 0.013 |
| DBIL | 2.40 [1.59, 3.40] | 2.30 [1.50, 3.43] | 2.50 [1.63, 3.38] | 0.199 |
| TP | 66.80 [62.30, 69.90] | 66.30 [61.70, 71.10] | 66.90 [62.50, 69.20] | 0.636 |
| ALB | 40.00 [36.50, 42.50] | 39.90 [36.50, 42.70] | 40.20 [36.80, 42.30] | 0.764 |
| GLB | 26.30 [23.50, 29.40] | 26.30 [22.30, 30.60] | 26.30 [24.30, 28.60] | 0.897 |
| A/G | 1.54 [1.31, 1.75] | 1.52 [1.26, 1.81] | 1.55 [1.34, 1.71] | 0.943 |
| Urea | 5.89 [4.74, 7.56] | 5.73 [4.58, 7.20] | 6.05 [4.99, 7.64] | 0.059 |
| CREA | 78.80 [66.00, 92.30] | 76.60 [63.70, 91.90] | 82.00 [68.60, 93.10] | 0.004 |
| UA | 330.00 [278.00,394.00] | 326.00 [265.00,398.00] | 332.00[288.00,393.00] | 0.180 |
| CEA | 3.69 [2.11, 9.74] | 3.70 [2.05, 9.43] | 3.68 [2.25, 9.81] | 0.556 |
| PE | <0.001 | |||
| No | 608 (75.20%) | 353 (87.40%) | 255 (63.10%) | |
| Yes | 200 (24.80%) | 51 (12.60%) | 149 (36.90%) | |
| Gender | <0.001 | |||
| Male | 683 (84.50%) | 315 (78.00%) | 368 (91.10%) | |
| Female | 125 (15.50%) | 89 (22.00%) | 36 (8.90%) | |
| Drink | <0.001 | |||
| No | 683 (84.50%) | 377 (93.30%) | 306 (75.70%) | |
| Yes | 125 (15.50%) | 27 (6.70%) | 98 (24.30%) | |
| Smoke | <0.001 | |||
| No | 518 (64.10%) | 322 (79.70%) | 196 (48.50%) | |
| Yes | 290 (35.90%) | 82 (20.30%) | 208 (51.5%) | |
| Diabetes | 0.999 | |||
| No | 731 (90.50%) | 366 (90.60%) | 365 (90.30%) | |
| Yes | 77 (9.50%) | 38 (9.40%) | 39 (9.70%) | |
| Hypertension | 0.667 | |||
| No | 636 (78.70%) | 321 (79.50%) | 315 (78.00%) | |
| Yes | 172 (21.30%) | 83 (20.50%) | 89 (22.00%) | |
| CHD | 0.008 | |||
| No | 759 (93.90%) | 370 (91.60%) | 389 (96.30%) | |
| Yes | 49 (6.10%) | 34 (8.40%) | 15 (3.70%) | |
| Stage | 0.053 | |||
| Stage I | 29 (3.60%) | 21 (5.20%) | 8 (2.00%) | |
| Stage II | 96 (11.90%) | 46 (11.40%) | 50 (12.40%) | |
| Stage III | 330 (40.80%) | 171 (42.30%) | 159 (39.40%) | |
| Stage IV | 353 (43.70%) | 166 (41.10%) | 187 (46.30%) | |
| Histology | 0.005 | |||
| Adenocarcinoma | 327 (40.50%) | 183 (45.30%) | 144 (35.60%) | |
| Squamous | 333 (41.20%) | 151 (37.40%) | 182 (45.00%) | |
| SCLC | 135 (16.70%) | 60 (14.90%) | 75 (18.60%) | |
| Other lung cancers | 13 (1.60%) | 10 (2.50%) | 1 (0.70%) | |
Statistically significant differences are marked with bold font.